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E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3 45Results: Zoledronic acid but not pamidronate has a cytotoxic
potential even at pharmacological dosage. Zoledronic acid does
not only induce apoptosis by inhibiting the Ras-pathway but
has also an anti-metastatic effect. Freshly prepared cd T cells con-
sisting mainly of Vd2 cells showed increased cytotoxicity against
bisphosphonate-treated pancreatic carcinoma cells. cd T cells
could be expanded fourfold by use of anti-CD3 and IL-2. However,
activated. cd T cells do not respond to bisphosphonates and kill
mainly in a Vd1 dependent manner.
Results: Our results demonstrate that zoledronic acid has a
direct apoptotic effect on pancreatic carcinoma cells and has
anti-metastatic properties. Tumor cells treated with zoledronic
acid are more susceptible against Vc9 Vd2 T cells, the most abun-
dant population of cd T cells in the peripheral blood. Treatment
with zoledronic acid for patients with pancreatic carcinoma
might be an option.
doi:10.1016/j.ejcsup.2006.04.109
P50. THE TETRASPANIN D6.1A INDUCES TUMOR
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Background: Tetraspanins are involved in cell activation, prolif-
eration, adhesion, motility and cell fusion. Some members
including D6.1A are known to promote metastasis formation.
Overexpression of the tetraspanin D6.1A on a rat pancreatic ade-
nocarcinoma line BSp73AS (BSp73AS-D6.1A) is associated with
the formation of haemorrhagic ascites and can induce dissemi-
nated intravascular coagulation.
Methods: Angiogenesis was analysed by intravital microscopy
of the rat mesentery 6 days after intraperitoneal tumor cell
application and after co-culture of the mesentery with tumor
cells, supernatant of the tumor cells and tumor cell derived
exosomes.
Results: D6.1A expressing tumor cells induced strong angio-
genesis with vessels covering roughly 25% of the tumor area
as compared to 5% in BSp73AS tumors. Also mesenteric cells
displayed strikingly increased branching in co-cultures with
BSp73AS-D6.1A cells, supernatant thereof or tumor cell derived
exosomes. A D6.1A-specific antibody completely inhibited
BSp73AS-D6.1A-, but also BSp73AS-induced angiogenesis
in vivo and in vitro. This finding suggested the existence of
an additional antibody target that has been identified as prolif-
erating endothelial cells, which strongly upregulate D6.1A
expression.
Conclusion: Tumor derived D6.1A is a strong angiogenesis indu-
cer, that indicates for an angiogenic loop due to the striking
upregulation of D6.1A on endothelial cells. Because of the latter,
the antibody-mediated suppression of the angiogenesis likely
offers a very effective and selective drug.
doi:10.1016/j.ejcsup.2006.04.110P51. DEFINING THE APOPTOTIC PATHWAYS UNDERLYING
HISTONE DEACETYLASE INHIBITOR-MEDIATED TUMOR
THERAPY
Ralph K. Lindemanna, Andrea Newbolda, Kate Whitecrossa,
Anthony E. Dearb, Clare L. Scottc, Andrew Weic, Victoria
Richond, Scott W. Lowee, Ricky W. Johnstonea. aPeter MacCallum
Cancer Centre, Cancer Immunology Program, Gene Regulation
Laboratory, East Melbourne, Vic. 3002, Australia; bMonash University,
Department of Medicine, Box Hill Hospital, Vic., Australia; cThe Walter
and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville,
Vic. 3050, Australia; dMerck and Co. Inc., Boston, MA, USA; eCold
Spring Harbor Laboratory, Bungtown Road, Cold Spring Harbor, NY
11724, USA.
Background: Histone deacetylase inhibitors (HDACi) are novel
anti-tumor compounds currently being tested in clinical trials.
Our laboratory has previously shown that in cultured cells
HDACi-induced cell death was mediated by mitochrondrial dam-
age, cytochrome C release and Bid cleavage. However, it is pres-
ently unclear which apoptotic pathways are utilized by HDACi
in vivo, i.e. in a therapeutic setting. Moreover, it is poorly under-
stood how molecular events during anti-cancer drug-mediated
apoptosis relate to therapeutic outcome.
Methods: We have employed the murine El-myc B-cell lym-
phoma model to directly compare HDACi-induced cell death
in vitro with therapeutic efficacy in vivo. Our system comprises
lymphomas with defined genetic alterations in the apoptotic
machinery and the tumors can either be grown and treated
in culture or transplated into immunocompetent animals for
therapy studies. Using this system, we have identified key
apoptotic molecules that not only control sensitivity of cultured
lymphoma cells to HDACi, but also determine therapeutic
outcome.
Results: Overexpression of Bcl2, previously linked to treatment
failure in human cancers, conferred complete chemoresistance
in vitro and in vivo. Strikingly, the HDACi SAHA eradicated El-
myc lymphomas in a p53-independent manner, resulting in pro-
longed survival after SAHA treatment of p53/ lymphomas.
Constraining the cellular apoptotic program by genetic targeting
of Apaf-1, Caspase-9 and Bid impinged on in vitro sensitivity
and we are currently investigating whether this is associated with
tumor relapse and chemoresistance while animals are under
therapy.
doi:10.1016/j.ejcsup.2006.04.111
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Introduction: The X-ray cross-complementing gene XRCC1 and
the excision repair cross-complementing group 2 gene ERCC2
(XPD) are involved in the repair of DNA modifications resulting
from DNA-damaging agents used in cancer therapy. Functional
46 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3polymorphisms in XRCC1 and ERCC2 leading to reduced DNA
repair capacity may be of benefit in cancer chemotherapy and
may prolong patient’s survival.
Methods: Overall survival (OS) was evaluated in 303 Caucasians
with primary lung cancer who received anticancer treatment that
include first-line chemotherapy using the statistical methods of
Kaplan–Meier curves and Cox proportional hazards model with
hazard ratios (HRs). DNA isolated from peripheral blood was gen-
otyped for XRCC1 (Arg280 His and Arg399Gln) and ERCC2 (Asp312Asn)
by fluorescence-based melting curve (LightCycler) analysis and
for XRCC1 (Arg194Trp) and ERCC2 (Lys751Gln) by PCR-RFLP.
Results: Among all lung cancer cases, only small cell lung cancer
(SCLC) patients carrying the XRCC1 399Arg allele had a reduced
overall survival (HR 2.13, 95%CI 0.92–4.92) compared to the homo-
zygous 399Gln genotype. When compared to XRCC1 Arg280His het-
erozygotes, 280Arg homozygotes showed increased survival being
significant only for SCLC patients (HR 0.31, CI 0.14–0.69). A signif-
icantly increased HR was found for ERCC2 751Gln homozygous car-
riers (HR 3.05, CI 1.20–7.73) for SCLC but not for non-SCLC.
Conclusion: The survival of lung cancer patients receiving che-
motherapy seems to be modified by certain repair gene polymor-
phisms notably in the subgroup of SCLC patients.
doi:10.1016/j.ejcsup.2006.04.112
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Introduction: A histoculture experimental system of colon can-
cer was studied to evaluate the reliability and utility of new bio-
logical approaches. The three-dimensional growth pattern of
the tissue, preserved by this technique is essential for observing
the oncogenic properties, differentiated functions and cellular
heterogeneity of the tumors. Colon cancer as one of the most
common neoplastic diseases worldwide was chosen as a model
for remedial testing with viruses with enhanced oncoselective
activities, as parvovirus H-1. Paralleled in vitro testing of sensitiv-
ity to the oncolytic H-1 parvovirus, using experimental systems of
both cell lines and organotipic cultures of colon cancer, will sup-
port a better prediction of the in vivo response of patient with this
type of cancer.
Methods: Samples from 30 patients with primary untreated
colorectal carcinomas were set in histoculture. This technique
has been reported as a reliable system, in which tumours can
be cultivated with high efficiency by the transfer of human
tumour samples to collagen sponges. H-1 virus in the treated tis-
sue samples and the colon cancer cell lines was detected by IHC
and RT-PCR. Immunofluorescence was used to characterize the
protein patterns of cellular E-cadherin and viral proteins. Tissue
growth inhibition was determined by calculating glucose con-
sumption rates.Results: The analyses revealed significant differences in the
response of the five different human colon cancer cell lines to
H-1 wt parvovirus infectivity and killing abilities. Increased per-
missiveness of the colon cancer cells to virus killing was corre-
lated to the lower expression pattern of E-cadherin. Higher
virus toxicity was measured in colon cancer cells, over-trans-
formed with SV40 large T-antigen. Growth inhibition assays per-
formed in histocultures showed slight reduction on tissue
viability after H-1 wt infection, compared to the stronger effects
after 5-FU treatment. RT-PCR and IHC revealed the presence of
viral transcripts and viral proteins in the samples, which showed
reduced tissue metabolism after infection.
Conclusion: All examined colon cancer cell lines showed a heter-
ogenic response to H-1 parvovirus infectivity. The genetic back-
ground of the cell lines showed that cells characterized as
aneuploid exert better permissivness to virus infectivity. Straight-
forward correlation was observed between the E-cadherin expres-
sion pattern and sensitivity to virus infection. The weak effects
observed after tissue treatment with H-1 wt parvovirus, are due to
the intrinsic cellular heterogeneity of the tumor tissues and confirm
the higher virus oncotropism, with selective killing of the tumor
cells in the original samples, but not their normal counterparts.
doi:10.1016/j.ejcsup.2006.04.113
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Background: The genetic alterations and expression rates of the
molecular markers, associated with prognosis of patients with
lung cancer (LC) were investigated. Biomarker expression levels
were compared in groups of patients with different histological
types and survival rates.
Methods: Tumor samples from 54 patients with NSCLC were
analyzed in a retrospective study of paraffin-embedded tissues
by immunohistochemistry and in fresh frozen biopsies by RT-
PCR. The expression of MMP2, MMP9, b-catenin, E-cadherin,
CAV1, Ki67 were evaluated.
Results: Normal membrane-bound E-cadherin expression was
absent in 80% of the squamous cell LC, 69.2% adenocarcinomas,
85.7% bronchoalveolar carcinomas The normal membrane bound
form of b-catenin was absent almost in all bronchoalveolar carci-
nomas, but it preserved partly in 40% cases of squamous cell LC
and in 53.8% of adenocarcinomas. The MMP2 expression was
common for squamous cell and for bronchoalveolar cancer (60–
71%), but was absent in SCLC. There was no correlation between
the frequency and intensity of expression of adhesion molecules
and proliferation index. The expression of caveolin and RALGDS
was also compared with clinical parameters. The prognostic sig-
nificance of each marker and their complexes was analysed.
Conclusions: Abnormalities in adhesion molecules is common
for different lung carcinomas. Frequency and intensity of expres-
